These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 36884207)

  • 21. Human leukocyte antigen epitope mismatch loads and the development of de novo donor-specific antibodies in cardiothoracic organ transplantation.
    Bedford A; Jervis S; Worthington J; Lowe M; Poulton K
    Int J Immunogenet; 2022 Feb; 49(1):30-38. PubMed ID: 34904369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive value of HLAMatchmaker and PIRCHE-II scores for de novo donor-specific antibody formation after adult and pediatric liver transplantation.
    Hamada S; Dumortier J; Thévenin C; Pageaux GP; Faure S; Guillaud O; Boillot O; Lachaux A; Luscalov DA; Dubois V; Meszaros M
    Transpl Immunol; 2020 Aug; 61():101306. PubMed ID: 32422222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between SARS-CoV-2 infection and de novo HLA donor specific antibody production in lung transplant recipients: Single-center study.
    Shah SZ; Abdelmoneim Y; Pham SM; Elrefaei M
    Hum Immunol; 2022 Nov; 83(11):749-754. PubMed ID: 35987702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-human leukocyte antigen and anti-ABO antibodies after SARS-CoV-2 mRNA vaccination in kidney transplant recipients.
    Nishida H; Takai S; Ito H; Fukuhara H; Nawano T; Narisawa T; Kanno H; Yagi M; Yamagishi A; Sakurai T; Naito S; Tsuchiya N
    Clin Transplant; 2023 May; 37(5):e14952. PubMed ID: 36846878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes.
    Wiebe C; Pochinco D; Blydt-Hansen TD; Ho J; Birk PE; Karpinski M; Goldberg A; Storsley LJ; Gibson IW; Rush DN; Nickerson PW
    Am J Transplant; 2013 Dec; 13(12):3114-22. PubMed ID: 24164958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HLA-DQ mismatches stimulate de novo donor specific antibodies in heart transplant recipients.
    Zhang X; Kransdorf E; Levine R; Patel JK; Kobashigawa JA
    Hum Immunol; 2020 Jul; 81(7):330-336. PubMed ID: 32307126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Formation of donor-specific antibodies depends on the epitope load of mismatched HLAs in lung transplant recipients: A retrospective single-center study.
    Lobashevsky A; Niemann M; Kowinski B; Higgins N; Abdel-Wareth L; Atrabulsi B; Roe D; Hage C
    Clin Transplant; 2022 Sep; 36(9):e14755. PubMed ID: 35771140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
    Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
    Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of donor specific antibodies after SARS-CoV-2 vaccination in kidney and heart transplant recipients.
    McCune TR; Bray RA; Baran DA; Toepp AJ; Forte SJ; Gilgannon LT; Williams T; Chen S; Sadr H; Gebel HM; Herre JM
    Transpl Immunol; 2022 Dec; 75():101722. PubMed ID: 36152939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Class II HLA Eplet Mismatch Is a Risk Factor for De Novo Donor-Specific Antibody Development and Antibody-mediated Rejection in Kidney Transplantation Recipients.
    Kishikawa H; Kinoshita T; Hashimoto M; Fukae S; Taniguchi A; Yamanaka K; Nakagawa M; Nishimura K
    Transplant Proc; 2018 Oct; 50(8):2388-2391. PubMed ID: 30316363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Donor/Recipient HLA Molecular Mismatch Scores Predict Primary Humoral and Cellular Alloimmunity in Kidney Transplantation.
    Meneghini M; Crespo E; Niemann M; Torija A; Lloberas N; Pernin V; Fontova P; Melilli E; Favà A; Montero N; Manonelles A; Cruzado JM; Palou E; Martorell J; Grinyó JM; Bestard O
    Front Immunol; 2020; 11():623276. PubMed ID: 33776988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Class II Human Leukocyte Antigen Epitope Mismatch Predicts De Novo Donor-Specific Antibody Formation After Liver Transplantation.
    Kubal CA; Mangus R; Ekser B; Mihaylov P; Ceballos B; Higgins N; Chalasani N; Ghabril M; Nephew L; Lobashevsky A
    Liver Transpl; 2018 Aug; 24(8):1101-1108. PubMed ID: 30142248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and infectious outcomes in pediatric kidney transplant recipients after COVID-19 vaccination: A pediatric nephrology research consortium study.
    Churilla T; Crane C; Sreedharan R; Alzarka BJ; Charnaya O; Jain NG; Pizzo H; Mansuri A; Jain A; Grewal M; Fishbein JD; Kula AJ; Heald-Sargent T; Matossian D; Verghese PS
    Pediatr Transplant; 2024 Jun; 28(4):e14786. PubMed ID: 38766983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eplet mismatch scores and de novo donor-specific antibody development in simultaneous pancreas-kidney transplantation.
    Ladowski JM; Mullins H; Romine M; Kloda D; Young C; Hauptfeld-Dolejsek V; Houp J; Locke J
    Hum Immunol; 2021 Mar; 82(3):139-146. PubMed ID: 33390268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. C3d-binding Donor-specific HLA Antibody Is Associated With a High Risk of Antibody-mediated Rejection and Graft Loss in Stable Kidney Transplant Recipients: A Single-center Cohort Study.
    Lee DR; Kim BC; Kim JP; Kim IG; Jeon MY
    Transplant Proc; 2018 Dec; 50(10):3452-3459. PubMed ID: 30503524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Snowflake epitope matching correlates with child-specific antibodies during pregnancy and donor-specific antibodies after kidney transplantation.
    Niemann M; Strehler Y; Lachmann N; Halleck F; Budde K; Hönger G; Schaub S; Matern BM; Spierings E
    Front Immunol; 2022; 13():1005601. PubMed ID: 36389845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
    Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
    Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination.
    Al Jurdi A; Gassen RB; Borges TJ; Solhjou Z; Hullekes FE; Lape IT; Efe O; Alghamdi A; Patel P; Choi JY; Mohammed MT; Bohan B; Pattanayak V; Rosales I; Cravedi P; Kotton CN; Azzi JR; Riella LV
    Front Immunol; 2022; 13():838985. PubMed ID: 35281011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Immunogenicity of HLA Class II Mismatches: The Predicted Presentation of Nonself Allo-HLA-Derived Peptide by the HLA-DR Phenotype of the Recipient Is Associated with the Formation of DSA.
    Jucaud V
    J Immunol Res; 2017; 2017():2748614. PubMed ID: 28331856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors, histopathological features, and graft outcome of transplant glomerulopathy in the absence of donor-specific HLA antibodies.
    Senev A; Van Loon E; Lerut E; Callemeyn J; Coemans M; Van Sandt V; Kuypers D; Emonds MP; Naesens M
    Kidney Int; 2021 Aug; 100(2):401-414. PubMed ID: 33675843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.